Why Sustainable Biomanufacturing Must Start Earlier in The Process
Beyond Reporting - Safety surveillance analytics for medical devices...
AI is in Every Pharma Strategy Deck
LYMPHOMA TREATMENT AT A CROSSROADS
Long-acting Injectable Formulations
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
GE Healthcare
President & CEO
Our current business focus and strengths are in the areas of bioprocessing proteins cellular analysis cell handling and tools for cell therapy Our strategic intent is to add adjacent technologies or applications which can add value to the overall customer solutions we provide
We are particularly excited about the sample collection and storage opportunity with the FTA product lineWe have a stron...
Articles
CAR-T Cell Therapy and NexCAR19
Radiation therapy chemotherapy and surgery have been the cornerstones of cancer treatment for many years While they remain essential therapy pillars recent advancements in the field have significantly changed the treatment landscape for cancer patients
Research Insights
Drug-induced Liver Injury Prediction Based on Graph Convolutional Networks and Toxicogenomics
Druginduced liver injury is a leading cause of high attrition rates for both candidate drugs and marketed medications Previous in silico models may not effectively utilize biological drug property information and often lack robust model validation In this study
Case Studies
Analytics Stories: A Case Study from Quintiles
As I have shared within other posts within this series businesses are using analytics to improve their internal and external facing business processes and to strengthen their right to win within the markets that they operate For pharmaceutical businesses strengthening the right to win begins and ends with the drug product development lifecycle I remember for example t...
Techno Trends
Aprea Therapeutics to Treat Myelodysplastic Syndromes
Aprea Therapeutics has launched a mutant p reactivating compound APR in combination with chemotherapy drug azacitidine for the treatment of Myelodysplastic Syndromes MDS in patients having a susceptible TP mutation
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Artificial Intelligence - A current and future tool to learn chemical sciences
Ruchi Bharti received her M.Sc. from Patna University, in organic chemistry. PhD from National Institute of Technology Patna (NIT Patna), in 2012. There she worked on the development of new organocatalysts and their utilization in the synthesis of diverse heterocyclic compounds via multimulticomponent reactions. In 2017, she enrolled as assistant professor at R. P Sharma Institute of Technology, Since 2018, she joined Department of Chemistry, University Institute of Sciences, Chandigarh University, Punjab as Assistant Professor. Her recent research work is focused on the functionalisation of diverse heterocycles, multicomponent reactions, organocatalysis and their related biological and medicinal applications.
How Ready are Cellulose Nanocrystals in Delivery of Anticanceragents?
Researcher, Donghua University
Significance of Bioinformatics in Precision Oncology
Pravitha Kasu Sivanandan holds an MSc in Bioinformatics from Bharathiyar University, India, and works as a Bioinformatician at MVR Cancer Centre & Research Institute. She specializes in multi-omics data analysis, focusing on stratified healthcare. She focuses on potential of bioinformatics in precision oncology. Pravitha is also an Associate Member of AACR.
Covid -19 and Nanoparticles
Ramendra Pati Pandey is an Assistant Professor in the Department of Biotechnology/Microbiology/Biomedical Engineering at the SRM University, Delhi-NCR, Sonepat. He was a FAPESP Post-Doctoral Fellow a very prestigious fellowship of Latin America at the Department of Medicine-InCor/HC-FMUSP, University of Sao Paulo, Brazil.
Deepika has completed here master degree from Department of Biotechnology, Deenbandhu Choturam University and Technology, Sonepat, Haryana, India.
Reshma completed her master's degree from the Royal Global University in Guwahati, Assam, India's department of Biotechnology.
Neehasri holds a master's degree in Zoology from Gauhati University in Guwahati, Assam, India, and has also passed the B.Ed. professional exam.
Probiotics as live Biomolecules to Manage Sleep Disorders
Sumel Ashique, Assistant Professor at Bharat Technology, is an accomplished pharmaceutical scientist with 150+ publications, 5 patents, and expertise in drug delivery and nanotechnology. He serves as a reviewer and guest editor for reputed journals and is currently pursuing a Ph.D. at Lovely Professional University, Punjab.
Mohini Mondal, Assistant Professor at Bharat Technology, is a dedicated pharmaceutics academic and researcher. With an M. Pharm and ongoing Ph.D., she specializes in drug delivery systems and holds an IP for an innovative ocular gel. Her work bridges teaching and research, shaping future pharmaceutical professionals.
press releasesRead more...
Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program
Pfizer Inc NYSE PFE and Blackstone Life Sciences Blackstone today announced a strategic cofunding agreement under which funds managed by Blackstone will pay up to a total of billion of development
Circio and Solid Biosciences enter collaboration to evaluate circVec and POLARIS-101 technology for Genetic Heart Disease
Circio Holding ASA OSE CRNA a biotechnology company developing novel circular RNA expression technology for gene and cell therapy today announces a research collaboration with Solid Biosciences Inc
EirGenix and Merck enter Partnership to Strengthen Global Biologics Development Through Integrated BioReliance® Testing and Regulatory Support
EirGenix Inc and Merck have signed a nonlegally binding memorandum of understanding MOU to support EirGenixs IND and BLA enabling biologics pipeline development The MOU outlines Merck as one of EirGenixs preferred contract testing services vendors providing comprehensive BioReliance services
ProBio Enters Exclusive Global Licensing Agreement with AbTis to Develop Next-Generation ADC Asset
ProBio a global contract research development and manufacturing organization CRDMO today announced that it has entered into an exclusive global licensing agreement with AbTis Co Ltd
AGC Biologics partners with Child’s Cure Genetic Research to pursue mRNA-based therapeutic for severe epileptic disorder
In a world where patients with CDKL deficiencies can suffer to epileptic seizures a day a contract biopharmaceutical manufacturer and a parentfounded foundation will partner on earlystage
Rakovina Therapeutics Secures Exclusive Worldwide Licence to Artemis.AI™ Platform for DNA-Damage Response Oncology Drug Discovery
Rakovina Therapeutics Inc TSXV RKV FSE JO OTCMKTS RKVTF a biopharmaceutical company advancing innovative cancer therapies through AIpowered drug discovery today announced
EventsRead more...
11 - 13
Nov 2026Frontiers in Cancer Science 2026
One Farrer Hotel,1 Farrer Park...
11 - 12
Nov 2026Medical Device Project and Portfolio Management
Chicago, IL, USA
16 - 17
Nov 2026Analytics for Smarter Decisions in Pharma
London, UK
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
01 - 03
Dec 2026Pharmaceutical Launch Excellence Summit
Novotel Amsterdam City, Nether...
01 - 03
Dec 202610th Antifibrotic Drug Development
Boston, MA at the Hotel Common...
LATEST NEWSRead more...
Natera Enters into Collaboration with Incyte for Phase II Trial in Colorectal Cancer
Natera a precision medicine company has entered into a clinical collaboration with Incyte to support a new Phase II study evaluating an investigational treatment for colorectal cancer CRC
Shionogi Enters into Licence Agreement with Link for Antibiotic Cefiderocol
Shionogi has entered into a licence agreement with Link Healthcare Singapore to develop and commercialise cefiderocol in Singapore and Malaysia
IDEL Therapeutics Partners with Daiichi Sankyo to Develop Multi-Drug Conjugates for Solid Tumours
IDEL Therapeutics has entered into a global research collaboration with Daiichi Sankyo to evaluate a multidrug conjugate MDC using iDELs synthetic shuttle platform for the treatment of selected solid tumours The multiyear collaboration will focus on the preclinical evaluation of a new class of MDCs...
Bayer’s Asundexian Receives Approval for Secondary Stroke Prevention
Bayer has received approval from the US Food and Drug Administration FDA for asundexian mg tablets marketed under the brand name Sunharbo to reduce the risk of recurrent stroke in adults following a recent noncardioembolic ischaemic stroke or highrisk transient ischaemic attack TIA
Johnson & Johnson Receives Approval for RYBREVANT FASPRO to Treat Advanced Head and Neck Cancer
Johnson Johnson has received accelerated approval from the US Food and Drug Administration FDA for RYBREVANT FASPRO amivantamab and hyaluronidaselpuj to treat adults with recurrent or metastatic head and neck squamous cell carcinoma HNSCC
Boehringer Ingelheim Enters into Partnership with SBP Group to Advance Next-Generation Cancer Therapies
Boehringer Ingelheim and Sino Biopharmaceutical SBP Group have entered into a multiprogram partnership to develop potential nextgeneration cancer treatments using antibodydrug conjugate ADC and Tcell engager TcE technologies
